TY - JOUR T1 - Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London JF - medRxiv DO - 10.1101/2020.05.24.20110346 SP - 2020.05.24.20110346 AU - Jie Zhou AU - Jonathan A. Otter AU - James R. Price AU - Cristina Cimpeanu AU - Danel Meno Garcia AU - James Kinross AU - Piers R Boshier AU - Sam Mason AU - Frances Bolt AU - Alison H. Holmes AU - Wendy S. Barclay Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.24.20110346.abstract N2 - Background Evaluation of SARS-CoV-2 surface and air contamination during the COVID-19 pandemic in London.Methods We performed this prospective cross-sectional observational study in a multi-site London hospital. Air and surface samples were collected from seven clinical areas, occupied by patients with COVID-19, and a public area of the hospital. Three or four 1.0 m3 air samples were collected in each area using an active air sampler. Surface samples were collected by swabbing items in the immediate vicinity of each air sample. SARS-CoV-2 was detected by RT-qPCR and viral culture; the limit of detection for culturing SARS-CoV-2 from surfaces was determined.Results Viral RNA was detected on 114/218 (52.3%) of surfaces and 14/31 (38.7%) air samples but no virus was cultured. The proportion of surface samples contaminated with viral RNA varied by item sampled and by clinical area. Viral RNA was detected on surfaces i and in air in public areas of the hospital but was more likely to be found in areas immediately occupied by COVID-19 patients than in other areas (67/105 (63.8%) vs. 29/64 (45.3%) (odds ratio 0.5, 95% confidence interval 0.2-0.9, p=0.025, Chi squared test)). The high PCR Ct value for all samples (>30) indicated that the virus would not be culturable.Conclusions Our findings of extensive viral RNA contamination of surfaces and air across a range of acute healthcare settings in the absence of cultured virus underlines the potential risk from environmental contamination in managing COVID-19, and the need for effective use of PPE, physical distancing, and hand/surface hygiene.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JAO reports personal fees from Gama Healthcare Ltd and Pfizer in the past three years outside the submitted work; Dr. Kinross reports grants from H2020 (ITN grant), NIHR (i4i grant), CRUK fellowship, personal fees from Verb robotics / Ethicon and Medtronic, and other relationships with Cerulean Health, One Welbeck day surgery, and LNC therapeutics; all other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, all other authors report no other relationships or activities that could appear to have influenced the submitted work.Funding StatementNational Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Infections in partnership with Public Health England (PHE), in collaboration with, Imperial Healthcare Partners, University of Cambridge and University of Warwick supported this work. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or Public Health England. Professor Alison Holmes is a National Institute for Health Research (NIHR) Senior Investigator. International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) provided funding for JZ and laboratory materials used for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work was registered locally as an NHS service evaluation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to this work will be shared upon request. ER -